Telara Pharma - focused and committed to kidney disease improvement.

focused and committed to kidney disease improvement.

Home
Science
Pipeline
About Us
News

Category Archives: Paper

Telara Pharma > News > Paper

20

Aug

Date August 20, 2025

Author TelaraPharma Tags Dr. Alberto Lázaro, The Cilastatin project

New paper published: Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity

Martín-Ramírez R, González-Nicolás MÁ, Álvarez-Tosco K, Machín F, Ávila J, Morales M, Lázaro A, Martín-Vasallo P.Cells....

Author TelaraPharma

16

Aug

Date August 16, 2025

Author TelaraPharma Tags Arch Biopartners, Dr. Alberto Lázaro, The Cilastatin project

New paper published: Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis.

https://www.mdpi.com/1422-0067/26/16/7927 González-Nicolás MÁ, Humanes B, Herrero R, Arenillas M, López B, Ferruelo A, Lore...

Author TelaraPharma

Search for:

Categories

Arch Biopartners 4
Award 3
Paper 2
TelaraPharma 14

Recent Posts

New paper published: Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral NeurotoxicityAugust 20, 2025
New paper published: Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis.August 16, 2025
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)July 24, 2025
DESARROLLO DE UN NUEVO AGENTE PROTECTOR DE LA APOPTOSIS, LA CILASTATINA, DIRIGIDO AL TRATAMIENTO DE PROCESOS NEURODEGENERATIVOSJune 30, 2025
Telara Pharma Earns Emerging Company Certification from EnisaMay 27, 2025

Tags

Arch Biopartners Dr. Alberto Lázaro Dr. Alberto Tejedor GENESIS Biomed Gregorio Marañon IiSGM renal injury The Cilastatin project

Archives

August 2025
July 2025
June 2025
May 2025
September 2024
August 2024
June 2024
April 2024
April 2023
June 2021
May 2021
April 2021
November 2020

Telara Pharma is a global leader in repurposing the drug cilastatin to make new therapies for severe inflammatory disorders like Acute Kidney Injury (AKI).

Menu

Home
Pipeline
About Us
News
Contact

SCIENCE

Problem
Solution
Specific Data
Papers

RECENT POST

New paper published: Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity August 20, 2025
New paper published: Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis. August 16, 2025

Copyright © 2025 TelaraPharma. All rights reserved.